Phase 3 trial of COVID begins to prevent infection

Phase 3 trial of COVID begins to prevent infection

Image=Wikipedia

[Newsphopick=Gyubin Lee] An antibody cocktail is now beginning late-stage clinical trials to evaluate the drug's ability to prevent and treat coronavirus infection. The biotechnology company Regeneron announced the late-stage clinical trials of REGN-COV2, its investigational double-antibody cocktail for the treatment and prevention of Covid-19, in a news release on Monday.

Specifically, the release noted that a Phase 3 trial of the drug will assess its ability to prevent coronavirus infection among uninfected people who have had close contact with an infected person, such as a patient's housemate. The Phase 3 prevention trial is happening at around 100 sites and expected to include 2,000 patients across the United States, according to Regeneron. 

The drug also has moved into the Phase 2/3 portion of two trials testing its ability to treat hospitalized and non-hospitalized patients with Covid-19, according to Regeneron. These trials will involve 1,850 hospitalized patients and 1,050 non-hospitalized patients, and they are expected to be conducted at 150 sites in the United States, Brazil, Mexico, and Chile. 

"We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic," Dr. George D. Yancopoulos, co-founder, president, and chief scientific officer of Regeneron, said in the company's news release. 

The release also noted that the trial is being run jointly with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

0
0
이 글을 페이스북으로 퍼가기 이 글을 트위터로 퍼가기 이 글을 카카오스토리로 퍼가기 이 글을 밴드로 퍼가기